Nick Brake, a 58-year-old diagnosed with young-onset Alzheimer's in 2024, is utilizing lecanemab via private funding to manae his condition. His experience highlights a growing disparity in the UK between available medical breakthroughs and NHS accessibility.
NICE's rejection of lecanemab creates a private-pay divide
The Medicines and Healthcare products Regulatory Agency approved lecanemab in August 2024, but the National Institute for Health and Care Excellence (NICE) subsequently rejected it for NHS funding. As the report states, NICE determined that the drug's clinical benefits were too small to justify its high cost. This decision leaves a significant portion of the 70,000 Britons living with Alzheimer's without access to the first treatment capable of clearing amyloid protein from the brain.
Lecanemab functions as an antibody treatment that assists the brain's immune system in removing the sticky proteins linked to the disease. While this represents a massive shift in how the condition is managed, the financial barrier to entry means that the most effective tools may only be available to those with significant personal wealth.
Why donepezil was insufficent for a lifelong runner
For Nick Brake, the limitations of standard NHS options were compounded by his personal physiology and the subtle onset of his symptoms. Before his diagnosis, Brake experienced cognitive lapses, such as struggling to recall a Gothic archway logo from his former furniture business. As the report notes, his wife Nicky first noticed him asking how to spell basic words and struggling to maintain conversations.
While the NHS typically offers cholinesterase inhibitors like donepezil and rivastigmine to ease symptoms, these 1990s-era drugs do not treat the underlying brain damage. Furthermore, Brake could not safely take the highest dose of donepezil because the medication can slow the heart rate—a significant risk for a lifelong runner like Brake, who already maintains a naturally low resting heart rate.
A grueling first infusion at the Cleveland Clinic
Seeking more aggressive intervention, Brake began his private treatment regimen in January 2025 under the supervision of consultant neurologist Dr. Richard Perry at the Cleveland Clinic in London. The transition to this new therapy was not without physical hardship; Brake's first infusion caused a severe reaction that left him feeling "frozen" for approximately 36 hours.
Since that initial incident, the medical team has managed the side effects using paracetamol and antihistamines before infusions. brake's treatment schedule has evolved from an hour-long infusion every two weeks to a more stable monthly routine, which he believes is helping to hold his condition steady.
The unanswered question of equitable access for 70,000 Britons
While Brake has found a way to manage his disease, his experience raises difficult questions about the future of dementia care in the UK. The source does not clarify if there are any active appeals regarding the NICE decision or if other patients are successfully navigating this private-pay route to avoid the limitations of the NHS.
Furthermore, the emotional toll of this medical divide is evident in the Brake family's sense of guilt. While Nick believes the drug should be available to all , it remains unknown whether the NHS will eventually adjust its cost-benefit analysis as more data on lecanemab becomes available, or if a permanent two-tier system for Alzheimer's care is being established.
Comments 0